Anti-inflammatory effects of ang-(1-7) in ameliorating HFD-induced renal injury through LDLr-SREBP2-SCAP pathway

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Zheng, Yaning ^a   Tang, Lin ^a   Huang, Wenhan ^a   Yan, Ruyu ^a   Ren, Feifeng ^a   Luo, Lei ^a   Zhang, Ling ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN[1-7]; LOW DENSITY LIPOPROTEIN RECEPTOR; PEPTIDES AND PROTEINS; PROTEIN SCAP; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UNCLASSIFIED DRUG; ANGIOTENSIN I; ANGIOTENSIN I (1-7); ANTIINFLAMMATORY AGENT; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG MECHANISM; FEEDBACK SYSTEM; KIDNEY INJURY; LIPID DIET; LIPID STORAGE; MALE; MOUSE; NONHUMAN; PROPHYLAXIS; SIGNAL TRANSDUCTION; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; DRUG EFFECTS; DYSLIPIDEMIAS; IMMUNOLOGY; INFLAMMATION; KIDNEY; LIPID METABOLISM; PATHOLOGY;

ACUTE KIDNEY INJURY; ANGIOTENSIN I; ANIMALS; ANTI-INFLAMMATORY AGENTS; DIET, HIGH-FAT; DYSLIPIDEMIAS; INFLAMMATION; KIDNEY; LIPID METABOLISM; MALE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; RECEPTORS, LDL; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

EID: 84942878370     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136187     Document Type: Article

References (48)

1. Felizardo RJ, da Silva MB, Aguiar CF, Camara NO. Obesity in kidney disease: A heavyweight opponent. World J Nephrol 2014; 3: 50-63. doi: 10.5527/wjn.v3.i3.50 PMID: 25332896
2. Decleves AE, Mathew AV, Cunard R, Sharma K. AMPK Mediates the Initiation of Kidney Disease Induced by a High-Fat Diet. J Am Soc Nephrol 2011; 22: 1846-55. doi: 10.1681/ASN.2011010026 PMID: 21921143
3. Lee W, Eom DW, Jung Y, Kim S, Jeon Y, Yamabe N, et al. Dendrobium moniliforme attenuates high-fat diet-induced renal damage in mice through the regulation of lipid-induced oxidative stress. Am J Chin Med 2012; 40: 1217-28. doi: 10.1142/S0192415X12500905 PMID: 23227793
4. Harcourt BE, Forbes JM, Matthews VB. Obesity-induced renal impairment is exacerbated in interleukin-6-knockout mice. Nephrology (Carlton) 2012; 17: 257-62.
5. Zhang HM, Dang H, Kamat A, Yeh CK, Zhang BX. Geldanamycin derivative ameliorates high fat dietinduced renal failure in diabetes. PloS one 2012; 7: e32746. doi: 10.1371/journal.pone.0032746 PMID: 22412919
6. Coimbra TM, Janssen U, Grone HJ, Ostendorf T, Kunter U, Schmidt H, et al. Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 2000; 57: 167-82. PMID: 10620198
7. Lee HS, Jeong JY, Kim BC, Kim YS, Zhang YZ, Chung HK. Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. Kidney Int 1997; 51: 1151-9. PMID: 9083281
8. Kasiske BL, O'Donnell MP, Schmitz PG, Kim Y, Keane WF. Renal injury of diet-induced hypercholesterolemia in rats. Kidney Int 1990; 37: 880-91. PMID: 2313977
9. Xu ZE, Chen Y, Huang A, Varghese Z, Moorhead JF, Yan F, et al. Inflammatory stress exacerbates lipid-mediated renal injury in ApoE/CD36/SRA tripe knockout mice. Am J Physiol Renal Physiol 2011; 301: 713-22.
10. Sun H, Yuan Y, Sun ZL. Cholesterol Contributes to Diabetic Nephropathy through SCAP-SREBP-2 Pathway. Int J Endocrinol 2013; 2013: 592576. doi: 10.1155/2013/592576 PMID: 24369464
11. Chen Y, Ruan XZ, Li Q, Huang A, Moorhead JF, Powis SH, et al. Inflammatory cytokines disrupt LDLreceptor feedback regulation and cause statin resistance: a comparative study in human hepatic cells and mesangial cells. Am J Physiol Renal Physiol 2007; 293: 680-7.
12. Ruan XZ, Varghese Z, Powis SH, Moorhead JF. Dysregulation of LDL receptor under the influence of inflammatory cytokines: A new pathway for foam cell formation. Kidney Int 2001; 60: 1716-25. PMID: 11703589
13. Mercadel L, Metzger M, Haymann JP, Thervet E, Boffa J, Flamant M, et al. The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease. PloS one 2014; 9: e99781. doi: 10.1371/journal.pone.0099781 PMID: 24978810
14. Gariballa S, Kosanovic M, Yasin J, Essa AE. Oxidative damage and inflammation in obese diabetic emirati subjects. Nutrients 2014; 6: 4872-80. doi: 10.3390/nu6114872 PMID: 25375631
15. Mangge H, Becker K, Fuchs D, Gostner JM. Antioxidants, inflammation and cardiovascular disease. World J Cardiol 2014; 6: 462-77. doi: 10.4330/wjc.v6.i6.462 PMID: 24976919
16. Santos SH, Andrade JM, Fernandes LR, Sinisterra R, Sousa F, Feltenberger JD, et al. Oral Angiotensin-( 1-7) prevented obesity and hepatic inflammation by inhibition of resistin/TLR4/MAPK/NF-kappaB in rats fed with high-fat diet. Peptides 2013; 46: 47-52. doi: 10.1016/j.peptides.2013.05.010 PMID: 23714175
17. Stemmer K, Perez-Tilve D, Ananthakrishnan G, Bort A, Seeley RJ, Tschop MH, et al. High-fat-dietinduced obesity causes an inflammatory and tumor-promoting microenvironment in the rat kidney. Dis Model Mech 2012; 5: 627-35. doi: 10.1242/dmm.009407 PMID: 22422828
18. Wang X, Lin Y, Luo N, Chen Z, Gu M, Wang J, et al. Short-term intensive atorvastatin therapy improves endothelial function partly via attenuating perivascular adipose tissue inflammation through 5-lipoxygenase pathway in hyperlipidemic rabbits. Chin Med J (Engl) 2014; 127: 2953-9.
19. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J Endocrinol 2013; 216: R1-R17. doi: 10. 1530/JOE-12-0341 PMID: 23092879
20. Santos SH, Andrade JM. Angiotensin 1-7: A peptide for preventing and treating metabolic syndrome. Peptides 2014; 59C: 34-41.
21. Santos RA, Ferreira AJ. Angiotensin-(1-7) and the renin-angiotensin system. Curr Opin Nephrol Hypertens 2007; 16: 122-8. PMID: 17293687
22. Grobe N, Elased KM, Cool DR, Morris M. Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney. Am J Physiol Endocrinol Metab 2012; 302: E1016-24. doi: 10.1152/ajpendo. 00515.2011 PMID: 22318946
23. Joyner J, Neves LA, Granger JP, Alexande BT, Merrill DC, Chappell MC, et al. Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats. Am J Physiol Regul Integr Comp Physiol 2007; 293: R169-77. PMID: 17428896
24. Bosnyak S, Widdop RE, Denton KM, Jones ES. Differential mechanisms of ang (1-7)-mediated vasodepressor effect in adult and aged candesartan-treated rats. Int J Hypertens 2012; 2012: 192567. doi: 10.1155/2012/192567 PMID: 22187625
25. Fraga-Silva RA, Costa-Fraga FP, De Sousa FB, Alenina N, Bader M, Sinisterra RD, et al. An orally active formulation of angiotensin-(1-7) produces an antithrombotic effect. Clinics (Sao Paulo, Brazil) 2011; 66: 837-41.
26. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 2006; 290: H2417-23. PMID: 16415071
27. Regenhardt RW, Desland F, Mecca AP, Pioquinto DJ, Afzal A, Mocco J, et al. Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke. Neuropharmacology 2013; 71: 154-63. doi: 10.1016/j. neuropharm.2013.03.025 PMID: 23583926
28. Santos SH, Fernandes LR, Mario EG, Ferreira AV, Porto LC, Alvarez-Leite JI, et al. Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 2008; 57: 340-7. PMID: 18025412
29. Santos SH, Braga JF, Mario EG, Porto LC, Rodrigues-Machado MG, Murari A, et al. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arterioscler Thromb Vasc Biol 2010; 30: 953-61. doi: 10.1161/ATVBAHA.109.200493 PMID: 20203301
30. Zhang J, Noble NA, Border WA, Huang Y. Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am J Physiol Renal Physiol 2010; 298: F579-88. doi: 10.1152/ajprenal.00548.2009 PMID: 20032116
31. Giani JF, Burghi V, Veiras LC, Tomat A, Munoz MC, Cao G, et al. Angiotensin-(1-7) attenuates diabetic nephropathy in Zucker diabetic fatty rats. Am J Physiol Renal Physiol 2012; 302: F1606-15. doi: 10. 1152/ajprenal.00063.2012 PMID: 22492942
32. Giani JF, Munoz MC, Pons RA, Cao G, Toblli JE, Turyn D, et al. Angiotensin-(1-7) reduces proteinuria and diminishes structural damage in renal tissue of stroke-prone spontaneously hypertensive rats. Am J Physiol Renal Physiol 2011; 300: F272-82. doi: 10.1152/ajprenal.00278.2010 PMID: 20962118
33. Zhang K, Meng X, Li D, Yang J, Kong J, Hao P, et al. Angiotensin(1-7) attenuates the progression of streptozotocin-induced diabetic renal injury better than angiotensin receptor blockade. Kidney Int 2014; 87:359-6. doi: 10.1038/ki.2014.274 PMID: 25075768
34. Huang W, Tang L, Cai Y, Zheng Y, Zhang L. Effect and mechanism of the Ang-(1-7) on human mesangial cells injury induced by low density lipoprotein. Biochem Biophys Res Commun 2014; 450: 1051-7. doi: 10.1016/j.bbrc.2014.06.107 PMID: 24978313
35. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S. Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism: clinical and experimental 1987; 36: 54-9.
36. Hamilton MT, Hamilton DG, Zderic TW. Role of low energy expenditure and sitting in obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease. Diabetes 2007; 56: 2655-67. PMID: 17827399
37. Boini KM, Zhang C, Xia M, Poklis JL, Li PL. Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. J Pharmacol Exp Ther 2010; 334: 839-46. doi: 10.1124/jpet.110. 168815 PMID: 20543095
38. Lai YH, Chen LJ, Cheng JT. Role of TNF-alpha in renal damage in mice showing hepatic steatosis induced by high fat diet. Horm Metab Res 2013; 45: 38-42. doi: 10.1055/s-0032-1321871 PMID: 22956307
39. Tomiyama-Hanayama M, Rakugi H, Kohara M, Mima T, Adachi Y, Ohishi M, et al. Effect of interleukin-6 receptor blockage on renal injury in apolipoprotein E-deficient mice. Am J Physiol Renal Physiol 2009; 297: F679-84. doi: 10.1152/ajprenal.90680.2008 PMID: 19570877
40. Mori J, Patel VB, Abo Alrob O, Basu R, Altamimi T, Desaulniers J, et al. Angiotensin 1-7 ameliorates diabetic cardiomyopathy and diastolic dysfunction in db/db mice by reducing lipotoxicity and inflammation. Circ Heart Fail 2014; 7: 327-39. doi: 10.1161/CIRCHEARTFAILURE.113.000672 PMID: 24389129
41. da Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa W, et al. Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol 2010; 185: 5569-76. doi: 10.4049/jimmunol.1000314 PMID: 20935211
42. Esteban V, Heringer-Walther S, Sterner-Kock A, de Bruin R, van den Engel S, Wang Y, et al. Angiotensin-( 1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. PloS one 2009; 4: e5406. doi: 10.1371/journal.pone.0005406 PMID: 19404405
43. Alfie J, Aparicio LS, Waisman GD. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition. Rev Recent Clin Trials 2011; 6: 134-46. PMID: 21241234
44. Meune C, Wahbi K, Duboc D, Weber S. Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function. J Cardiovasc Pharmacol Ther 2011; 16: 368-75. doi: 10.1177/1074248410391667 PMID: 21193681
45. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158, 998 patients. Eur Heart J 2012; 33: 2088-97. doi: 10.1093/eurheartj/ ehs075 PMID: 22511654
46. Santos EL, de Picoli Souza K, da Silva ED, Batista EC, Martins PJ, D, Almeida V, et al. Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. Biochem Pharmacol 2009; 78: 951-8. doi: 10.1016/j.bcp.2009.06.018 PMID: 19549507
47. Furuhashi M, Ura N, Takizawa H, Yoshida D, Moniwa N, Murakami H, et al. Blockade of the reninangiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 2004; 22: 1977-82. PMID: 15361770
48. Feltenberger JD, Andrade JM, Paraiso A, Barros LO, Filho AB, Sinisterra RD, et al. Oral formulation of angiotensin-(1-7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice. Hypertension 2013; 62: 324-30. doi: 10.1161/HYPERTENSIONAHA.111.00919 PMID: 23753417